ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Characteristic exploration of Mycobacterium tuberculosis isolated from patients with linezolid-treated multidrug-resistant tuberculosis.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Synergism in drug combination of new tuberculosis antibiotics for drug-resistantMicrobiology spectrum · 2026Article
- Molecular Mechanisms Underlying Antimicrobial Resistance in Mycobacteria.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
synopsis
objectivesLinezolid (LZD) is crucial for treating multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB); however, mutations related to LZD resistance still need to be characterised. This study investigated resistance-related mutations on a whole-genome scale in clinical isolates from patients with MDR/XDR TB who failed LZD treatment.
methodsThe phenotypic drug susceptibility test (DST) of first- and second-line anti-tuberculosis drugs was determined using the Sensititre™ plate; the Resazurin Microtitre Assay settled the minimal inhibitory concentration (MIC) of LZD. Overall, 25 sequential isolates previously collected and deposited in the Masan National TB Hospital (MNTH) Biobank were used. All included patients had MDR/XDR TB with failed LZD-included treatment. All isolates were subjected to whole-genome sequencing using the Illumina
resultsOf the 25 isolates, 18 were LZD resistant at the lowest MICs ≥ 1 mg/L and showed LZD resistance after 3 months of treatment; 20 had mutations in the rplC or rrl genes; 4 had G2814T mutations in rrl. 11 isolates harboured the T460C mutation in rplC. The G2814T mutant in rrl or the T460C mutant in rplC were resistant to LZD MICs up to 8 mg/L. One linezolid-resistant isolate harboring G2814T and T460C mutations exhibited MIC values greater than 16 mg/L. Conversely, seven isolates did not exhibit genetic mutations in rrl or rplC. Significant mutations or changes were observed when sequential isolates from the same patient were compared.
conclusionsThe study findings demonstrate mutations related to LZD resistance, which can aid in the detection of LZD resistance and optimisation of treatment regimens for patients with LZD-treated MDR/XDR TB.
Indexed as
Identifiers
41160260What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.